MARIMED INC. DL-,001

MariMed achieved a record revenue of $41.9m in the second quarter (+6% q/q and y/y) and slightly beat the revenue estimate; adjusted EBITDA rose to $3.9m with adjusted EPS of -$0.01, in line with expectations. Growth came from both wholesale and retail; branded products grew faster than the industry in core markets. Margins remained below last year’s level and the market reacted negatively: the stock fell about 8% and is trading near its 52-week low. Management expects mid-term margin improvements from higher utilization, business maturation and market expansion (Ohio, New York) despite ongoing price pressure. » More on de.investing.com

MariMed reported revenue of $39.5 million in Q1 2026 (+4.2% y/y), slightly above the $39.3 million forecast. Earnings per share were a loss of $0.01, in line with expectations; operating income and operating cash flow improved, and the net loss narrowed versus the prior year. The stock remained unchanged at $0.084 after the release. For Q2 the company expects moderate revenue increases to $40.95 million, stable EPS, and continues to focus on expanding retail and wholesale channels as well as operational efficiency. » More on de.investing.com

MariMed reported Q4 2025 EPS of $2.20 and revenue of $41.7 million, with both metrics comfortably topping analyst expectations. The full-year results showed revenue rising to $159.8 million and Non-GAAP-EBITDA of $16.9 million (margin 10.5%). Despite the strong figures, the stock fell 2.35% and was trading near its 52-week low, weighed down by ongoing price pressure in established markets and broad weakness in the cannabis sector. MariMed expects further growth from market expansion, product innovation and operational efficiency, but cites regulatory and macroeconomic risks. » More on de.investing.com